PE20091808A1 - Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica - Google Patents

Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica

Info

Publication number
PE20091808A1
PE20091808A1 PE2009000519A PE2009000519A PE20091808A1 PE 20091808 A1 PE20091808 A1 PE 20091808A1 PE 2009000519 A PE2009000519 A PE 2009000519A PE 2009000519 A PE2009000519 A PE 2009000519A PE 20091808 A1 PE20091808 A1 PE 20091808A1
Authority
PE
Peru
Prior art keywords
dronedarone
diuretic
therapeutics
association
application
Prior art date
Application number
PE2009000519A
Other languages
English (en)
Inventor
David Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39684441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091808(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20091808A1 publication Critical patent/PE20091808A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN AGENTE ANTIARRITMICO TAL COMO DRONEDARONA; Y B) UN DIURETICO NO AHORRADOR DE POTASIO TAL COMO LOS TIAZIDICOS, OSMOTICOS, INHIBIDORES DE LA ANHIDRASA CARBONICA, ENTRE OTROS, CON EXCEPCION DE FUROSEMIDA, HIDROCLOROTIAZIDA, METOLAZONA, AMILORIDA, ESPIRONOLACTONA Y MANITOL. DICHA COMPOSICION REGULA EL NIVEL DE POTASIO EN LA SANGRE SIENDO UTIL EN LA PREVENCION DE HIPOCALEMIA EN PACIENTES CON HIPERTENSION, TAQUICARDIA, CARDIOPATIA VALVULAR REUMATICA, FIBRILACION VENTRICULAR
PE2009000519A 2008-04-17 2009-04-15 Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica PE20091808A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802128A FR2930149B1 (fr) 2008-04-17 2008-04-17 Association de dronedarone avec au moins un diuretique, son application en therapeutique
US4599908P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
PE20091808A1 true PE20091808A1 (es) 2009-12-03

Family

ID=39684441

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000519A PE20091808A1 (es) 2008-04-17 2009-04-15 Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica

Country Status (26)

Country Link
US (1) US20110136899A1 (es)
EP (1) EP2280700A2 (es)
JP (1) JP2011517694A (es)
KR (1) KR20110005245A (es)
CN (1) CN102065856A (es)
AR (1) AR071326A1 (es)
AU (1) AU2009241966A1 (es)
BR (1) BRPI0910559A2 (es)
CA (1) CA2721560A1 (es)
CL (1) CL2009000918A1 (es)
CO (1) CO6300842A2 (es)
CR (1) CR11735A (es)
DO (1) DOP2010000308A (es)
EA (1) EA201071203A1 (es)
EC (1) ECSP10010552A (es)
FR (1) FR2930149B1 (es)
IL (1) IL208749A0 (es)
MA (1) MA32355B1 (es)
MX (1) MX2010011401A (es)
NI (1) NI201000171A (es)
PE (1) PE20091808A1 (es)
SV (1) SV2010003702A (es)
TW (1) TW200951117A (es)
UY (1) UY31772A (es)
WO (1) WO2009133310A2 (es)
ZA (1) ZA201007390B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072950A1 (es) 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (fr) * 2000-01-17 2002-04-05 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
FR2817864B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817865B1 (fr) * 2000-12-11 2005-02-18 Sanofi Synthelabo Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) * 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) * 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
US20090076137A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
AR072950A1 (es) * 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
EP2133075A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2153830A1 (en) * 2008-08-07 2010-02-17 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) * 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Also Published As

Publication number Publication date
CO6300842A2 (es) 2011-07-21
WO2009133310A2 (fr) 2009-11-05
ZA201007390B (en) 2012-01-25
CR11735A (es) 2010-11-22
MA32355B1 (fr) 2011-06-01
JP2011517694A (ja) 2011-06-16
IL208749A0 (en) 2010-12-30
NI201000171A (es) 2012-01-23
US20110136899A1 (en) 2011-06-09
WO2009133310A3 (fr) 2009-12-23
AU2009241966A1 (en) 2009-11-05
CN102065856A (zh) 2011-05-18
MX2010011401A (es) 2011-03-02
CL2009000918A1 (es) 2010-06-11
ECSP10010552A (es) 2010-11-30
FR2930149B1 (fr) 2011-02-18
FR2930149A1 (fr) 2009-10-23
EA201071203A1 (ru) 2011-06-30
BRPI0910559A2 (pt) 2015-09-22
TW200951117A (en) 2009-12-16
KR20110005245A (ko) 2011-01-17
CA2721560A1 (fr) 2009-11-05
EP2280700A2 (fr) 2011-02-09
SV2010003702A (es) 2011-03-04
UY31772A (es) 2009-12-14
AR071326A1 (es) 2010-06-09
DOP2010000308A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
CL2011002700A1 (es) Marcador de eventos ingerible altamente confiable y metodo para el uso del mismo.
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
AR061887A1 (es) Una composicion de vacuna contra el dengue
AR110174A2 (es) Agentes endoparasiticidas y procedimiento de preparación
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
PE20131063A1 (es) Composicion acuosa que contiene bromhexina
PE20091808A1 (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica
AR061772A1 (es) Composicion de alto contenido de ion fluoruro para el cuidado oral y metodo para mantener la actividad anticaries
ECSP066808A (es) Solución oftálmica que comprende carboximetilcelulosa de sodio e hidroxipropilmetilcelulosa
CR10408A (es) Composiciones novedosas para el trastornos del cabello y procedimiento de preparacion de las mismas
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
CO6040038A1 (es) Composiciones de ciclopropeno
BR112015006790A2 (pt) composição de cetoprofeno tópico
GT200600294A (es) Mezclas fungicidas a base de bifenilamidas de ácido pirazolcarboxílico 3-monosustituidas
BR112015013986A2 (pt) composições de cuidado oral estáveis ao peróxido
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
CR20110190A (es) Agente rodenticida sinérgico
PE20061365A1 (es) Composiciones farmaceuticas de liberacion modificada
ECSP10010683A (es) Una formulacion farmacéutica sólida
PE20140104A1 (es) Composiciones farmaceuticas que comprenden alisporivir
PE20090524A1 (es) Composicion farmaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina
CO2021005679A2 (es) Composiciones que comprenden celulosa oxidada
PE20121537A1 (es) Combinacion de teobromina con un descongestivo
PE20221272A1 (es) Agente supresor del sabor desagradable
BRMU8603015U (pt) agente farmacêutico contendo hialuronano como componente ativo

Legal Events

Date Code Title Description
FC Refusal